Adipiplon

drugbox
IUPAC_name = 7- [(2-(3-fluoropyridin-2-yl)-1H-imidazol-1-yl)methyl] -2-methyl-8-propyl- [1,2,4] triazolo [1,5-c] pyrimidine

---

width = 250
CAS_number = 840486-93-3
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C=18|H=18|F=1|N=7
molecular_weight = 351.38 g/mol
smiles = n4c(C)nc1n4cnc(c1CCC)Cn2ccnc2-c3ncccc3F
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Investigational New Drug
routes_of_administration =

Adipiplon (NG2-73) is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

Adipiplon is a subtype selective GABA_A partial agonist, which binds preferentially to the α₃ subtype. This is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for α_2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which is able to discriminate between α₂ and α₃, as well as showing little affinity for the α₁ or α₅ subtypes - alpidem is selective for α₃ over α₂, but still has moderate affinity for α₁, whereas adipiplon is highly α₃-selective with little affinity for either α₁, α₂ or α₅.

Adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and is currently (as of 2008) in Phase IIb trials. [ [http://www.neurogen.com/products/gaba%20insomnia.html Pipeline Summary GABA: Adipiplon] ] [ [http://www.drugs.com/clinical_trials/neurogen-announces-adipiplon-preclinical-clinical-data-presented-neuroscience-2007-2614.html Neurogen Announces Adipiplon Preclinical and Clinical Data] ] [ [http://www.sleepreviewmag.com/sleep_report/2007-09-12_07.asp Meet Adipiplon: The New Insomnia Drug] ]

References